As an Faculty member Danesh works to further understand cardiometabolic traits through combining cardiovascular epidemiology with genomic research techniques. His research focus is on providing novel insights into the causes and predictors of coronary heart disease.
Danesh’s research has helped to pioneer the use, at scale, of integrative population approaches to provide novel insights into the causes and predictors of coronary heart disease (CHD), demonstrating causal roles for interleukin-6 signalling, IL-1 signalling, and triglyceride-mediated pathways. His work on risk prediction has significantly influenced risk management, and has been cited in no less than 10 major guidelines since 2009. More recently, he has led major initiatives to improve the safety and efficiency of blood donation through strategic collaborations with NHS Blood and Transplant.
Danesh has been a leader and advocate of “team science” in international health research. For example, he created and direct the 2.5 million-participant Emerging Risk Factors Collaboration which elucidates the relevance of cardiovascular risk factors (>100 scientists from >25 countries) and the 520,000-participant pan-European EPIC-CVD consortium which studies the interplay of genetic and lifestyle factors (>60 scientists from 12 countries). He has led the creation of major bioresources that benefit the UK research community (eg, the 50,000-participant INTERVAL study) and the international research community (eg, as co-PI of studies in Bangladesh and Pakistan that have recruited >50,000 participants).
Danesh has helped shape national research strategy through external advisory roles (eg, MRC PSM Board, MRC Global Health Group, Wellcome Trust Genetics Panel, UK Biobank Steering Committee).
Since 2001, Danesh has led the Department of Public Health and Primary Care (University of Cambridge), one of Europe's leading academic population health departments, which has expanded >4-fold during his tenure (currently >400 members). He has helped to create joint appointments and innovative collaborations with strategic partners, including the NHS (eg, NHSBT), industry (eg, Pfizer-Cambridge Cardiovascular Genomics Centre), the not-for-profit sector (eg, RAND-Europe) and the Wellcome Trust Genome Campus.
Association of Cardiometabolic Multimorbidity With Mortality.
Glycated hemoglobin measurement and prediction of cardiovascular disease.
C-reactive protein, fibrinogen, and cardiovascular disease prediction.
The New England journal of medicine 2012;367;14;1310-20
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Lancet (London, England) 2012;379;9822;1205-13
Lipid-related markers and cardiovascular disease prediction.
Diabetes mellitus, fasting glucose, and risk of cause-specific death.
The New England journal of medicine 2011;364;9;829-841
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
Lancet (London, England) 2011;377;9771;1085-95
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
Lancet (London, England) 2010;375;9726;1634-9
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
Lancet (London, England) 2010;375;9725;1536-44
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
The New England journal of medicine 2004;350;14;1387-97
PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations.
Bioinformatics (Oxford, England) 2019
Genetic Risk Score for Coronary Disease Identifies Predispositions to Cardiovascular and Noncardiovascular Diseases.
Journal of the American College of Cardiology 2019;73;23;2932-2942
Genetically modulated educational attainment and coronary disease risk.
European heart journal 2019
Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease.
Circulation. Genomic and precision medicine 2019;12;5;e002376
Assessing the causal association of glycine with risk of cardio-metabolic diseases.
Nature communications 2019;10;1;1060
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries.
Nature genetics 2019;51;3;481-493
Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution.
Nature genetics 2019;51;3;452-469
Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.
Circulation. Genomic and precision medicine 2019;12;2;e002413
Genetic effects on promoter usage are highly context-specific and contribute to complex traits.
Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci.
Molecular psychiatry 2019
DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes.
Association of plasma vitamin D metabolites with incident type 2 diabetes: EPIC-InterAct case-cohort study.
The Journal of clinical endocrinology and metabolism 2018
Genomic atlas of the human plasma proteome.